CD56-Targeting ADC Found Safe and Active in Relapsed or Refractory Multiple Myeloma

Share this content:
Results from a phase 1 trial for the investigational ADC in multiple myeloma led investigators to conclude it may be viable in combination.
Results from a phase 1 trial for the investigational ADC in multiple myeloma led investigators to conclude it may be viable in combination.

A phase I study of the CD56-targeting lorvotuzumab mertansine showed the drug to be safe and active in patients with relapsed or refractory multiple myeloma.1

Lorvotuzumab mertansine is an antibody-drug conjugate targeting CD56, which is frequently expressed on multiple myeloma cells. Additionally, CD56 is expressed on less than 15% of normal cells, making it a useful marker of disease and an attractive therapeutic target. 

In this phase I study, 37 patients with relapsed myeloma were enrolled in a dose-escalation trial. Three patients each were enrolled at 40, 60, 75, 90, and 112 mg/mand 6 patients were enrolled at 140 mg/m2. Two patients experienced dose-limiting toxicities at the highest dose, so 112 mg/mwas established as the maximum-tolerated dose. An expansion phase included 16 additional patients treated at the 112 mg/mdose. 

Thirty-five of the 37 patients were included in the efficacy evaluable cohort. 

About six in 10 (56.8%) patients had relapsed or refractory myeloma. Despite that, stable disease or better was found in 42.9% of patients, with a median duration of response of 15.5 months. Partial response occurred in 5.7% of patients and 11.4% had minor response. No patient achieved very good partial response or complete response. Median progression-free survival was 26.1 weeks.

Eighty-nine percent of patients experienced an adverse event related to the study. Drug-related peripheral neuropathy occurred in 51% of patients. Grade 3 or 4 drug-related adverse events resulted in drug discontinuation in 9 patients; the most common event was peripheral neuropathy.

According to the researchers, “the safety and efficacy signal” from this ADC warrants its further clinical development — in combination with other agents — for patients with multiple myeloma. 

Disclosure: Authors of the original study declare various ties to pharmaceutical companies. For a full list of disclosures, please refer to the original study.


  1. Ailawadhi S, Kelly KR, Vescio RA, et al. A phase I study to assess the safety and pharmacokinetics of single-agent lorvotuzumab mertansine (IMGN901) in patients with relapsed and/or refractory CD-56-positive multiple myeloma [published online September 5, 2018]. Clin Lymphoma Myeloma Leuk.doi: 10.1016/j.clml.2018-08-018 

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs